Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of RV001V versus placebo in men with biochemical failure after curative therapy for localized prostate cancer
2019-000951-14Phase 2Completed
- Sponsor
- RhoVac AB
- Start
- May 2019
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing RV001V with Placebo (2 arms). Primary endpoint: Time to PSA progression. Started May 2019; status: completed.
02
Drugs
onilcamotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2019-000951-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000951-14.